RWE Fires Up 34 MW Hydrogen-Capable Turbine in Lingen as BlackRock Trims Stake to 7.12%

RWE has switched on a 34 MW gas turbine built with Kawasaki Heavy Industries at its Emsland power plant site in Lingen, launching a multi-month trial that will test electricity generation with up to 100% hydrogen. The companies announced the commissioning on Friday. For investors, the question now is whether to back the technical rollout of RWE's hydrogen strategy or wait for hard operating data — the trial opens a concrete testing phase whose value will only become clear from the results of the coming months.

The timing is notable. On Tuesday, RWE also secured awards from Germany's Federal Network Agency for hydrogen-ready power plant projects, meaning technical testing and announced construction are now advancing in parallel. Those tracking the story should weigh each strand separately before drawing conclusions.

Three Plants, 2,100 rMW, and a Build Start Weeks Away

The network agency awards cover three hydrogen-capable plants in Germany with a combined planned capacity of around 2,100 rMW. RWE has earmarked roughly 730 rMW for Voerde, with about 700 rMW each at Weisweiler and Werne. Construction of the first facility is due to begin in a few weeks, the company said Tuesday — a start date that applies to the first plant only, not all three sites. RWE has pledged billion-euro investments in connection with the projects.

Wind power is moving too. On 2 November, RWE commissioned the Serra Palino wind farm in Apulia, Italy, an eight-turbine installation with 47.2 MW of capacity.

What the Lingen Trial Must Prove

The decisive factor is how the hydrogen test unfolds. A more favorable read on RWE would be warranted if the turbine handles the planned operation convincingly over the trial period; the more robust the operating experience, the stronger Lingen's case as a technical foundation for future investment decisions. The commissioning itself is only the precondition — the next level would be reached if RWE can derive meaningful results from running operations and explain what they mean for further projects.

That creates a staged yardstick for shareholders: technical proof first, then a credible economic case. The clearer that link, the better a higher valuation can be justified. Until then, the trial remains above all a concrete development step.

Analysts Stay Positive, With 68 and 75 Euro Targets

Recent analyst moves fit a broadly constructive view. UBS reaffirmed its buy rating with a 68 euro price target on Wednesday, while Jefferies kept its buy call and 75 euro target on Tuesday. Jefferies analyst Ahmed Farman pointed to the auction success. Those endorsements carry more weight if RWE actually delivers on its announced steps — they form a positive valuation frame whose durability must be measured against execution.

The cautious scenario stems from the gap between technical progress and economic payoff. Should testing reveal a need for further adjustments, a reliable assessment of the hydrogen story could be pushed back. Meanwhile, the announced billion-euro investments raise the stakes on delivery: if construction lags the company's own announcements, the positive framing of the plant projects would need to be tempered, leaving the auction win as a starting point while actual execution decides how investors judge the stock.

BlackRock at 7.12% as Buyback Disclosures Roll In

BlackRock reported a total holding in RWE voting rights including instruments of 7.12%, down from 7.16% in its previous notification, according to a Tuesday filing. Separately, RWE disclosed share purchases under its buyback program for British entities on Thursday, covering acquisitions in November. An earlier disclosure on 2 November covered further purchases under the German employee share program for the final week of October.

Shares have gained 27% since the start of the year. After that run, the reaction to disappointing progress could be sharper if investors are already pricing in successful execution; a plan-compliant trajectory, by contrast, would reinforce the upbeat case. The balance between expectations and demonstrable progress therefore matters more for the share price than the mere count of new project announcements.

11 November 2026: The Next Fixed Checkpoint

The next scheduled date is 11 November 2026, when RWE publishes its interim statement for the first three quarters of 2026 and hosts an investor and analyst conference. That report will be the next concrete checkpoint for judging how business performance and the announced investments fit together. Those weighting the hydrogen story more heavily are betting on successful delivery across several stages; those wanting confirmation first will find it there. The multi-month Lingen trial, meanwhile, becomes the longer-running gauge on the technical side of that decision.